Enliven Therapeutics Shares Key Insights on ELVN-001 Data Update
Enliven Therapeutics Shares Key Insights on ELVN-001 Data Update
BOULDER, Colo. — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biotechnology firm dedicated to advancing precision oncology, is excited to share important details regarding the updated ELVN-001 Phase 1a data. This data has been chosen for an oral presentation at the highly regarded European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference. The conference is set to occur from September 27 to 29 in Prague.
Understanding ELVN-001
ELVN-001 is a highly selective small molecule kinase inhibitor designed to target the BCR-ABL gene fusion, known as the oncogenic driver in chronic myeloid leukemia (CML) patients. This innovative therapy aims to offer new hope in the treatment of this complex disease.
Presenting the Findings
The details of the oral presentation are crucial for those interested in the latest advancements in CML treatments. Here are the key specifics you need to know:
Presentation Overview
Title: Preliminary Safety and Efficacy of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1 in CML
Presenter: Fabian Lang, MD, from Goethe University Hospital
Session: Scientific Session 5: New Drugs and Combinations
Date/Time: Saturday, September 28, 3:00 - 4:20 p.m. CEST
Presentation Slot: 3:35 - 3:50 p.m. CEST / 9:35 - 9:50 a.m. ET
Availability of Presentation Materials
After the presentation, a copy of the materials will be accessible by visiting the Company’s website under the “Program Presentations & Publications” section. This transparency ensures that interested parties can stay informed about the findings and developments regarding ELVN-001.
About Enliven Therapeutics
Enliven Therapeutics is on a mission to improve the lives of individuals battling cancer through the discovery and development of small molecule inhibitors. The focus is not just on extending life but enhancing the quality of life for patients facing tough battles. With a robust approach to precision oncology, Enliven is addressing both present and emerging needs, driving forward the discovery of potential first-in-class or best-in-class therapies.
Engagement and Communication
For further inquiries, investors and media representatives can contact the Company directly. Enliven values the importance of maintaining open channels of communication.
Contact Information
Investors can connect via email at ir@enliventherapeutics.com.
Media inquiries can be directed to media@enliventherapeutics.com.
Frequently Asked Questions
What is ELVN-001 designed for?
ELVN-001 is designed to selectively target the BCR-ABL gene fusion, which is responsible for chronic myeloid leukemia (CML).
Where will the updated Phase 1a data be presented?
The data will be presented at the ESH-iCMLf 26th Annual John Goldman Conference in Prague.
When is the presentation scheduled?
The presentation will take place on September 28, during the 3:35 - 3:50 p.m. CEST timeslot.
How can I access the presentation materials?
Materials will be available on Enliven’s website in the “Program Presentations & Publications” section after the presentation.
How does Enliven Therapeutics support cancer patients?
Enliven aims to improve patient outcomes through innovative therapies that enhance both survival and quality of life for those battling cancer.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.